Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib vs Prednisone for Transplantation-related Autoimmune Cytopenia
ChiCTR2300077788Phase 4Recruiting
- Sponsor
- Medical Center of Hematology, Xinqiao Hospital, Army Medical University
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of ruxolitinib in autoimmune cytopenia (2 arms), sponsored by Medical Center of Hematology, Xinqiao Hospital, Army Medical University. Primary endpoint: Overall response rate after 6 months of treatment. Started Jul 2022; status: recruiting.
02
Drugs
03
Conditions
autoimmune cytopenia
Beyond the preview
Go deeper on ChiCTR2300077788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077788.